COMPASS Pathways (CMPS) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

—

Revenue (quarter)

—

Revenue growth (year over year)

—

Gross profit (trailing twelve months)

—

Gross margin

—

Net income (trailing twelve months)

—

Net income (quarter)

−$253.8M

Net income growth (year over year)

−560.87%

Net margin

—

Return on equity

−319.07%

EPS (trailing twelve months)

−$3.79

Book value per share

$0.62

P/E (trailing twelve months)

—

Price to book

18.02

Debt to assets

83.25%

Payout ratio

—

Dividend yield

—

Company profile

Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.

• How do I buy stock in COMPASS Pathways (CMPS)?

  CMPS trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.